Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection

Eik Schäfer1,2, Christian Scheer2, Karen Saljé1, Anja Fritz3, Thomas Kohlmann4, Nils-Olaf Hübner5,6, Matthias Napp7, Lizon Fiedler-Lacombe8, Dana Stahl8, Bernhard Rauch3, Matthias Nauck9,10, Uwe Völker11, Stephan Felix10,12, Guglielmo Lucchese13, Agnes Flöel13, Stefan Engel1, Wolfgang Hoffmann6, Klaus Hahnenkamp2 & Mladen V. Tzvetkov3*

We analyzed symptoms and comorbidities as predictors of hospitalization in 710 outpatients in North-East Germany with PCR-confirmed SARS-CoV-2 infection. During the first 3 days of infection, commonly reported symptoms were fatigue (71.8%), arthralgia/myalgia (56.8%), headache (55.1%), and dry cough (51.8%). Loss of smell (anosmia), loss of taste (ageusia), dyspnea, and productive cough were reported with an onset of 4 days. Anosmia or ageusia were reported by only 18% of the participants at day one, but up to 49% between days 7 and 9. Not all participants who reported ageusia also reported anosmia. Individuals suffering from ageusia without anosmia were at highest risk of hospitalization (OR 6.8, 95% CI 2.5–18.1). They also experienced more commonly dyspnea and nausea (OR of 3.0, 2.9, respectively) suggesting pathophysiological connections between these symptoms. Other symptoms significantly associated with increased risk of hospitalization were dyspnea, vomiting, and fever. Among basic parameters and comorbidities, age > 60 years, COPD, prior stroke, diabetes, kidney and cardiac diseases were also associated with increased risk of hospitalization. In conclusion, due to the delayed onset, ageusia and anosmia may be of limited use in differential diagnosis of SARS-CoV-2. However, differentiation between ageusia and anosmia may be useful for evaluating risk for hospitalization.

Thus far, SARS-CoV-2 infections have caused more than 6.2 million deaths worldwide1 and despite the development of effective vaccines, these infections still heavily influence daily life, economic activity and society worldwide.

Early diagnosis of a SARS-CoV-2 infection is pivotal to control the spread of the virus, pointing to the importance of the identification of specific symptoms with early manifestations. Fever, fatigue, cough, loss of smell and loss of taste are known symptoms of a SARS-CoV-2 infection2,3. However, most of the symptoms are nonspecific and may occur with different common viral infections. Furthermore, we need systematically collected data about the frequency and the time of onset of the symptoms of SARS-CoV-2 infection.

The severity of SARS-CoV-2 infection varies broadly among infected individuals and is difficult to predict in advance. Infected individuals may be asymptomatic, develop mild to moderate symptoms that do not require

1Department of Clinical Pharmacology, Institute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, Greifswald, Germany. 2Department of Anesthesiology, University Medicine Greifswald, Greifswald, Germany. 3Department of General Pharmacology, Institute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, 17489 Greifswald, Germany. 4Institute for Community Medicine, Section Epidemiology of Health Care and Community Health, University Medicine Greifswald, Greifswald, Germany. 5Central Unit for Infection Prevention and Control, University Medicine Greifswald, Greifswald, Germany. 6Institute of Hygiene and Environmental Medicine, University of Greifswald, Greifswald, Germany. 7Departments of Emergency and Acute Medicine, University Medicine Greifswald, Greifswald, Germany. 8Independent Trusted Third Party, University Medicine Greifswald, Greifswald, Germany. 9Department of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany. 10DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany. 11Department of Functional Genomics, University Medicine Greifswald, Greifswald, Germany. 12Department of Internal Medicine B, Cardiology, Pneumology, Infectious Diseases, Intensive Care Medicine, University Medicine Greifswald, Greifswald, Germany. 13Department of Neurology, University Medicine Greifswald, Greifswald, Germany. *email: mladen.tzvetkov@uni-greifswald.de
hospitalization, or need specialized medical care. Older age, male sex, and chronic kidney or cardiovascular disease are more commonly associated with a severe course of the disease and hospitalization. Symptoms like fever, cough and dyspnea were reported to be more common in patients who needed hospitalization. Less than 10% of infected individuals are admitted to a hospital. Out of them, about a quarter died in the hospital or during the immediate post-discharge period. The course of the infection in hospitalized patients is well described. The first detailed report was published by Zhu et al. and descriptions of severe disease courses have rapidly accumulated ever since.

Scores like 4C or CIRC (COVID-19 Inpatient Risk Calculator) have been developed to predict severity or mortality in COVID-19 patients after admission to a hospital. In their prediction, they include demographic factors, comorbidities, and even symptoms, but they are not directly transferable to outpatient setting.

However, the majority of the infected individuals (above 90%) do not require hospitalization. Prospective data collections in these patients are still rare, although they might help to establish an early diagnosis. Furthermore, these data should help to identify factors predicting hospitalization later in the course of the disease.

Here we report an observational cohort study on the course of SARS-CoV-2 infections in more than 700 outpatients in Germany. This study characterizes the course of symptoms during 25 days after infection aiming to identify specific symptoms and time patterns. We also analyzed symptoms and comorbidities as predictors for hospitalization.

**Methods**

**Study design and participants.** We performed a prospective observational cohort study of SARS-CoV-2 positive outpatients. With the help of the state office of health in the district of Vorpommern-Greifswald, Germany, we invited adults (18 years of age or older) with a PCR-confirmed SARS-CoV-2 infection to participate in our study. Study participants were asked to provide informed consent and to fill out two consecutive questionnaires. The first questionnaire pertained to demographics and comorbidities. The second one was a symptom diary covering the symptoms within the last 25 days after the start of the observational period. The start of the observational period was defined either as the day of occurrence of the first symptoms or as the day of the positive PCR test. The two questionnaires were sent together with an information sheet and a sheet with a brief overview about the study. Prepaid, pre-addressed envelopes were provided to return the documents back to the study center. For further information about our study, participants were invited to contact us by phone or e-mail. The only exclusion criterion was absence of a valid informed consent.

Our primary objective was to identify factors that may negatively influence the course of SARS-CoV-2 infections and lead to hospitalization in outpatients. The secondary objective was to describe the course of symptoms within the acute phase of the infection in patients with mild or moderate SARS-CoV-2 infection. The study was conducted in accordance with the 2013 Declaration of Helsinki and was approved by the Ethics Committee of the University Medicine Greifswald (internal Ethics Committee No.: BB 059/20). This study is registered in the German Clinical Trials Register (DRKS00021672).

To increase the power of identifying risk factors for hospitalization, we additionally included 143 participants hospitalized and treated for COVID-19 at Greifswald University Hospital, the largest hospital in the district of Vorpommern-Greifswald (ViP study, DRKS ID: DRKS00023770). The participants were recruited after hospitalization. ViP is an observation study to collect blood samples and medical data, such as previous medical conditions and current medication. Furthermore, medical data during the hospital stay, such as therapy-related medication and mechanical ventilation was collected.

**Questionnaire.** We developed a two-part questionnaire: one to collect possible risk factors present already before the infection and the second one in the form of a diary to self-document SARS-CoV-2 related symptoms over the first 25 days during the acute phase of the infection.

The first part of the questionnaire contained sociodemographic variables, such as gender, age, weight and pre-existing co-morbidities such as other chronic bacterial or viral infections, current medication, vaccination status, nutritional supplements and daily life activity. If a pre-existing disease was ticked “yes”, the participants could provide additional information. For this purpose, a detailed list of diseases was provided both in layman and medical terms, including heart diseases (coronary heart disease, heart failure, myocardial infarction), high blood pressure (systolic blood pressure before infection in different ranges), peripheral artery disease, diabetes mellitus (if known, Hba1c value in %), pulmonary diseases (asthma, COPD, obstructive sleep apnea), allergies (house dust allergy, allergic rhinitis), neurological diseases (stroke, multiple sclerosis, Parkinson’s disease, dementia), liver diseases (fatty liver, liver cirrhosis), renal diseases (diabetes, chronic kidney disease), joint diseases (rheumatoid arthritis, gout) and cancer of the lung, blood, breast or colon. It was possible to add other diseases within each organ system.

The second part of the questionnaire contained a table of 16 symptoms to be completed by the participant daily over 25 days after the onset of the initial symptoms. The symptoms were fever, dyspnea, dry cough, productive cough, headache, myalgia/arthritis, fatigue, anosmia, sore throat, conjunctivitis, skin manifestations, abdominal pain, diarrhea, nausea, and vomiting. When no symptoms had occurred before receiving our questionnaire, the day of the positive test was nominated to start with the table. In addition, we asked about the use of medication for the symptoms of COVID-19 and whether hospitalization was required. The questionnaire was provided in German language.

**Data management and statistical analyses.** Informed consent was checked by the Independent Trusted Third Party of the University Medicine Greifswald. The identifying personal data was removed from the questionnaires, which were pseudonymized and then forwarded to the study center where they were entered
Manual double data entry was used, followed by a quality check of the completed database. The participants were re-contacted via telephone in cases where data about hospitalization (primary endpoint) was missing, or if the participants returned the symptom diary before day 25, to solicit information about hospitalization connected to the infection. Regarding the symptom diary, missing data was imputed as “symptom not present” except if (i) symptoms reporting was discontinued for all symptoms by the participant before day 25, or (ii) the participant did not start reporting symptoms on the first day of the observation period. In these cases, we did not perform imputation and regarded the data as missing.

Statistical analyses were performed using IBM SPSS Statistics version 26. Medians and quartiles are used as descriptive statistics for continuous variables. Differences between groups of continuous variables were assessed using Mann–Whitney-U tests. Categorical variables are given in absolute numbers and percentages and differences in the distribution were assessed using Pearson's $\chi^2$ test. All the tests used were two-tailed. Binary logistic regression was used for multivariable analyses of effects on hospitalization.

### Results

#### Characteristics of the study population.

Between May 2020 and February 2021, we invited 3840 individuals who tested positive for SARS-CoV-2 to participate in the study. These represent 69.7% of all infections from the district of Vorpommern-Greifswald in the northeast of Germany (total population of 235,773) during the second infection wave (Supplementary Fig. 1). The remaining 30.3% were not invited because they were younger than 18 years, had missing address data, or their positive test result was older than 1 week. Nine-hundred-eighty-three individuals (25.6% of all invited) agreed to participate in the study, and 710 returned both questionnaires and were included in the analyses. Population characteristics and comorbidities are described in Table 1.

#### Frequency, duration and time course of the infection symptoms.

We asked patients to monitor 16 infection symptoms (Table 2). We received information about the symptoms from 700 out of 710 participants. Thirty-four individuals (4.9%) self-reported to have been completely asymptomatic during the entire observation period. Of the remaining participants, 622 reported the exact time point of the symptom onset related to the infection confirmation via PCR (Fig. 1: upper panel). The onset occurred on average 2.3 days before the confirmation of the infection by PCR test. Among the individuals with symptoms before the positive test result, 18.2% experienced the first symptom only one day before the test. At symptom onset, participants reported a median of three simultaneous symptoms with a range from 1 (134 participants) to 12 symptoms (1 participant, Fig. 1, lower panel). Importantly, the reported initial symptoms were nonspecific, e.g. fatigue (60.3%), headache (48.6%), myalgia/arthralgia (46.1%) or sore throat (29.3%, Supplementary Table 1). More SARS-CoV-2–specific symptoms, e.g. loss of smell or loss of taste, were reported by only 15.4% and 13.7%, respectively, on the day of symptom onset.

Fatigue was the most persistent symptom (mean duration of 12.1 days), followed by loss of smell, dyspnea, loss of taste and dry cough (each lasting more than 10 days on average, Table 2). In contrast, the symptoms with the shortest persistence were vomiting, fever, diarrhea, nausea and abdominal pain (each with mean duration

---

### Table 1. Basic characteristics and risk factors at baseline of the study population. Shown are median (first and third quartile) for age, BMI and grade of disability and absolute number (prevalence) for the remaining variables. *For differences between male and female participants (calculated using Pearson $\chi^2$ test except for age, BMI and grade of disability where Mann–Whitney U test was used).

| Parameter                        | All (n = 710) | Male (n = 285) | Female (n = 425) | p-value* |
|----------------------------------|--------------|---------------|-----------------|----------|
| Age in years                     | 53 (40–62)   | 55 (39–63)    | 52 (40–60)      | 0.067    |
| BMI in kg/m²                      | 26.6 (23.7–29.9) | 27.5 (24.7–30.5) | 25.9 (23.0–29.6) | 3.4 × 10⁻⁴   |
| Grade of disability in %         | 50 (30–60)   | 50 (40–70)    | 50 (30–60)      | 0.070    |
| Current smoker                   | 116 (16.3%)  | 45 (15.8%)    | 71 (16.7%)      | 0.746    |
| Former smoker                    | 231 (29.7%)  | 120 (42.1%)   | 91 (21.4%)      | 3.3 × 10⁻⁶   |
| Participants with at least one comorbidity (%) | 489 (68.9%) | 201 (70.5%) | 288 (67.8%) | 0.436 |
| Hypertension                     | 264 (37.2%)  | 117 (41.1%)   | 147 (34.6%)     | 0.081    |
| Allergy                          | 144 (20.3%)  | 49 (17.2%)    | 95 (22.4%)      | 0.094    |
| Joint diseases                   | 133 (18.7%)  | 55 (19.3%)    | 78 (18.4%)      | 0.752    |
| Cardiovascular diseases          | 80 (11.3%)   | 47 (16.5%)    | 33 (7.8%)       | 3.1 × 10⁻³   |
| Pulmonary diseases               | 64 (9.0%)    | 33 (11.6%)    | 31 (7.3%)       | 0.051    |
| Diabetes mellitus                | 61 (8.6%)    | 35 (12.3%)    | 26 (6.1%)       | 0.004    |
| Neoplasia                        | 56 (7.9%)    | 28 (9.8%)     | 28 (6.6%)       | 0.117    |
| Neurological diseases            | 50 (7.0%)    | 21 (7.4%)     | 29 (6.8%)       | 0.781    |
| Liver diseases                   | 49 (6.9%)    | 16 (5.6%)     | 33 (7.8%)       | 0.268    |
| Kidney diseases                  | 33 (4.6%)    | 15 (5.3%)     | 18 (4.2%)       | 0.526    |
| Peripheral artery disease        | 14 (2.0%)    | 8 (2.8%)      | 6 (1.4%)        | 0.190    |
| Participants with disability     | 138 (19.4%)  | 62 (21.8%)    | 76 (17.9%)      | 0.201    |
below 5 days, Table 2). Almost half of the participants (n = 239; 44.3%) reported at least one infection-related symptom on the last day of observation (day 25). Fatigue was the most frequently reported symptom on day 25 (n = 98, 18.2%, Fig. 2), followed by loss of smell (n = 83, 15.4%) and dry cough (n = 72, 13.4%; Fig. 2).

The frequency and duration of symptoms were sex-dependent. Women reported between 12 and 60% more commonly fatigue, loss of smell, loss of taste, headache, sore throat, abdominal pain, and nausea in the first 10 days of the infection and 23% of the women were still reporting fatigue at day 25 of the infection (Fig. 2, Supplementary Table 2).

The frequency and duration of some symptoms were also age-dependent. Younger participants (18–39 years) had shorter duration of fatigue, fever, arthralgia/myalgia, cough in any form, and skin lesions (Supplementary Table 4). On the other hand, fewer participants age 60 or above reported loss of smell and taste, headache, or sore throat (Supplementary Table 5), but when these symptoms occurred, their duration was not age-dependent (Supplementary Table 4).

Course of symptoms.  We observed two distinct patterns in the time course of symptoms. The majority of the symptoms were reported within the initial three days of the infection and the percentage of individuals reporting them declined consistently with time (Fig. 3, upper panel). Within this group, the most rapidly improving symptom was fever, with fewer than 2% of the participants reporting fever after day 12.

The second pattern is characterized by steadily increasing frequencies among the participants in the first week, reaching the peak at days 7 to 9 (Fig. 3, middle panel). Interestingly, the symptoms regarded as characteristic for the disease like loss of smell and taste followed this alternative pattern in our study. At day one only 17.1% of the participants reported loss of smell or loss of taste, whereas 48.8% of the participants suffered from loss of smell on day 7 (Fig. 3, middle panel).

Correlations between symptoms.  The strongest correlation was observed between the duration of loss of smell and loss of taste (r = 0.83, p < 0.001, Supplementary Fig. 2). However, these two symptoms differed in duration. Loss of smell was reported for a longer duration (mean 11.6 days, median 10 days) compared to loss of taste (mean 10.6 days, median 9 days; p = 1.2 × 10⁻⁸ paired t-test). Importantly, 50 individuals reported loss of smell without loss of taste and 26 individuals reported loss of taste without loss of smell (Fig. 3, lower panel).

Strong correlations were also observed between the duration of general symptoms (fatigue and arthralgia/myalgia, cough in any form, and skin lesions (Supplementary Table 4). On the other hand, fewer participants age 60 or above reported loss of smell and taste, headache, or sore throat (Supplementary Table 5), but when these symptoms occurred, their duration was not age-dependent (Supplementary Table 4).

Association of symptoms with hospitalization.  Next, we analyzed whether symptoms in outpatients may be predictive for the risk of hospitalization. Data about symptoms and hospitalization due to the infection

| Symptom                  | Number of individuals (% of all who answered) with the symptom | Median day of onset (range)* | Mean duration (days) |
|--------------------------|----------------------------------------------------------------|-----------------------------|----------------------|
|                          | At least 1 day | 5 or more days | 10 or more days |                          |                          |
| Fatigue                  | 557 (79.6%)   | 471 (67.3%)   | 314 (44.9%)   | 2 (1–15)               | 12.1                     |
| Headache                 | 487 (69.6%)   | 314 (44.9%)   | 151 (21.6%)   | 3 (1–20)               | 7.5                      |
| Dry cough                | 456 (65.1%)   | 360 (51.4%)   | 218 (31.1%)   | 3 (1–16)               | 10.6                     |
| Myalgia/arthralgia       | 443 (63.3%)   | 303 (43.3%)   | 128 (18.3%)   | 2 (1–20)               | 7.7                      |
| Loss of smell            | 375 (53.6%)   | 317 (45.3%)   | 195 (27.9%)   | 4 (1–13)               | 11.6                     |
| Loss of taste            | 351 (50.1%)   | 290 (41.4%)   | 161 (23.0%)   | 4 (1–17)               | 10.6                     |
| Sore throat              | 327 (46.7%)   | 165 (23.6%)   | 68 (9.7%)     | 3 (1–24)               | 6.3                      |
| Productive cough         | 251 (35.9%)   | 161 (23.0%)   | 102 (14.6%)   | 5 (1–24)               | 8.9                      |
| Diarrhea                 | 245 (35.0%)   | 76 (10.9%)    | 19 (2.7%)     | 4 (1–23)               | 3.8                      |
| Dyspnea                  | 224 (32.0%)   | 168 (24.0%)   | 115 (16.4%)   | 4 (1–17)               | 11.2                     |
| Nausea                   | 206 (29.4%)   | 81 (11.6%)    | 24 (3.4%)     | 4 (1–21)               | 4.6                      |
| Abdominal pain           | 180 (25.7%)   | 58 (8.3%)     | 23 (3.3%)     | 4 (1–23)               | 4.6                      |
| Fever ≥ 38 °C            | 180 (25.7%)   | 39 (5.6%)     | 5 (0.7%)      | 2 (1–21)               | 3.2                      |
| Skin manifestation       | 72 (10.3%)    | 47 (6.7%)     | 23 (3.3%)     | 7 (1–20)               | 8.0                      |
| Conjunctivitis           | 54 (7.7%)     | 25 (3.6%)     | 7 (1.0%)      | 7.5 (1–23)             | 5.3                      |
| Vomiting                 | 43 (6.1%)     | 3 (0.4%)      | 2 (0.3%)      | 6 (1–22)               | 2.2                      |

Table 2. Reported frequency, time of onset and persistence of symptoms. Symptoms are sorted according to their frequency starting with the most frequent one. *In relation to the onset of the first symptom, or in the case of an asymptomatic begin of the infection of the day of the positive PCR-test.
were available from 685 study participants, of which 36 participants (5.3%) were hospitalized. The median time between onset of the symptoms and hospitalization was 6 days (range 1 to 23 days).

Five symptoms were individually significantly associated with hospitalization (Fig. 4, upper panel). Vomiting, dyspnea and fever were associated with increased risk of hospitalization, while loss of smell and sore throat were associated with decreased risk (Fig. 4, upper panel).

Importantly, individuals who reported loss of taste without loss of smell (n = 26) were at close to sevenfold higher risk of hospitalization (Fig. 4, upper panel). The association remained significant after adjustment for age, sex and BMI (Fig. 4, lower panel). Furthermore, individuals who reported loss of taste without loss of smell more commonly experienced dyspnea and nausea (Fig. 5).

**Association between risk factors at baseline with hospitalization.** We also analyzed potential risk factors (demographic factors, comorbidities, and baseline medications) for associations with hospitalization. To enrich the participants in our study (36 participants hospitalized due to the infection), we analyzed 143 individuals hospitalized with COVID-19 in the University Hospital Greifswald (Supplementary Table 6), the major tertiary hospital in the region (ViP study, DRKS-ID: DRKS00023770). The resulting combined population included 838 persons infected with SARS-CoV-2, of which 179 (21.4%) participants were hospitalized due to the infection.
Age and BMI were highly significantly associated with risk of hospitalization (p < 10^{-26} and p = 0.004, respectively, Mann–Whitney–U Test; Supplementary Fig. 3). In addition to age above 60 years, male sex and the comorbidities cardiovascular disease, hypertension, diabetes mellitus, pulmonary disease (both general pulmonary disease and COPD specifically), neurological disease (both general neurological disease and stroke specifically), and kidney disease were associated with increased risk of hospitalization (Table 3). Of these, age, neurological disease, COPD, cardiac disease, and diabetes were independent predictors of hospitalization (Table 3). Liver diseases, joint diseases, allergy and neoplasia were not significantly associated with the risk of hospitalization.

Medications used to treat hypertension were also associated with the risk of hospitalization. ACE inhibitors and AT1-receptor blockers were associated with a similar risk increase (Table 3), but none of them was an independent predictor of risk of hospitalization.

Notably, disability of any grade was associated with a 3.1-fold increase in risk of hospitalization (Table 3). Only 3.9% of non-disabled participants were hospitalized, compared to 11.1% of disabled participants. However, these analyses were based only on the 36 hospitalized individuals from the outpatients study, as in the ViP study grade of disability was not documented.

Discussion
In this study, we analyzed the frequency and time course of SARS-CoV-2 infection in a large cohort of outpatients. We focused on identification of symptoms and comorbidities as risk factors associated with hospitalization. The main findings are the delayed onset of specific symptoms such as loss of smell and loss of taste. Most importantly, our data suggest that individuals reporting loss of taste but not loss of smell are more likely to suffer from progression of infection leading to hospitalization.

Loss of smell and loss of taste are regarded as relatively specific symptoms and therefore potentially useful in the differential diagnosis of SARS-CoV-2 infection\(^1\). Loss of smell or taste were among the five most commonly reported symptoms in the present study (Table 2). However, only 17.1% of our participants reported either of the two symptoms on the first day and 42.1% did not report loss of taste or loss of smell during the entire 25-day observation period (Fig. 3). This is in line with previously published outpatient studies\(^7,18\) and suggests that loss
Figure 3. Course of SARS-CoV-2 symptoms within the 25 day observational period. Shown are 10 of the analyzed 16 symptoms stratified according to their specific pattern: strongest initially (upper panel) and increasing until days 7 to 9 (middle panel). General symptoms are shown in gray, neurological in green, and pulmonary in blue. Skin manifestations, conjunctivitis, abdominal pain, diarrhea, nausea and vomiting are not shown because fewer than 15% of participants reported these symptoms on any observation day. The figures represent frequencies based on the original (non-imputed) data. The results using the imputed data are quite similar with the exception of fever as body temperature was much less frequently documented by the participants. The lower panel shows the correlation between duration of loss of taste and smell. Each individual is represented as a single dot. Hospitalized participants are represented in filled and non-hospitalized in open circles.
of smell or taste may be less useful as early markers of SARS-CoV-2 infection and PCR testing should also be triggered by less specific symptoms in order to detect infections earlier.

Our results support previous findings that loss of smell may be associated with lower risk for hospitalization\(^{19-21}\). Moreover, our study collected data starting at the early stages of the infection and may be less prone to underreporting of mild symptoms, which may occur at the time of hospitalization\(^{22,23}\).

Interestingly, our results indicate that isolated loss of taste without loss of smell predicts a higher risk of hospitalization (Fig. 4). To the best of our knowledge, this is the first report considering anosmia and ageusia as separate risk factors for hospitalization due to SARS-CoV-2 infection. An explanation may be found in the respective anatomy of the olfactory and gustatory sensory systems. The former consists of the first cranial nerve directly projecting to supratentorial structures, whereas the latter includes the nucleus of the solitary tract as first relay in the brainstem before moving upwards to the thalamus and the cortex\(^{24}\). Crucially, the nucleus of the solitary tract is part of the brainstem network regulating the respiratory and cardiac functions\(^{25,26}\). Therefore, loss of taste but not the loss of smell may be a direct marker of the SARS-CoV-2-induced brainstem damage contributing to the respiratory dysfunction in COVID-19\(^{19,27,28}\). We observed that loss of taste without loss of smell was significantly associated with dyspnea and nausea (Fig. 5), which further supports this hypothesis. Despite the biological plausibility of our results, independent replication is needed because of the limited number of hospitalized individuals in our study. Nevertheless, our data clearly point to separate consideration of both symptoms.

Our study emphasizes the multi-organ manifestations of SARS-CoV-2 infection. The increased risk for hospitalization we observed in participants with pulmonary symptoms like dyspnea (Fig. 4) or pulmonary

---

**Figure 4.** Association of symptoms with risk for hospitalization. Shown are the odds ratios and 95% confidence intervals without (upper panel) or after adjustment for age, sex and BMI (lower panel). Statistically significant associations are highlighted in bold and the levels of significance are reported (*p < 0.05, **p < 0.01, ***p < 0.001). The Pearson χ² test was used to calculate pairwise two-sided significances. Adjustment for age, sex and BMI was performed using binary logistic regression with hospitalization as the dependent variable and including the three adjustment parameters and each of the symptoms separately as dependent variables.
comorbidities like COPD (Table 3) is well described\(^{29–36}\). However, gastrointestinal symptoms like vomiting and cardiovascular and renal comorbidities also increased the risk for hospitalization. This is in line with previously reported data both about inpatients\(^{37–39}\) and outpatients\(^{40–43}\).

Notably, not only neurological symptoms, but also neurological comorbidities were among the strongest risk factors for hospitalization in our study (Table 3). We observed a 6.2-fold increased risk for hospitalization in infected individuals with a history of stroke. Respiratory infections are known to be more common in patients after stroke\(^{44–46}\), possibly due to brain-induced immunodepression\(^{47}\). Alternatively, post-stroke patients are at higher risk for deep vein thrombosis and pulmonary embolism, which may be exacerbated by SARS-CoV-2 infection and lead to hospitalization or death\(^{48,49}\). However, neurological comorbidities other than stroke were almost equally strongly associated with the risk for hospitalization (Table 3).

Disability was among the strongest predictors of hospitalization after SARS-CoV-2 infection in our study (Table 3). This confirms previous findings\(^{34}\) and may reflect that multiple comorbidities including both chronic disease and health conditions like Down syndrome, or mental disability increase the risk of hospitalization\(^{39,50,51}\). Whatever the underlying cause(s), our finding suggests that disability in general rather than the presence of a single comorbidity may be better for identifying individuals who may benefit from targeted preventive measures against SARS-CoV-2.

The association between comorbidities and hospitalization, which we observed in this study (Table 3), are in line with previous studies reporting hypertension\(^{52–54}\), diabetes\(^{45,53,54}\), COPD\(^{55,56}\) or kidney disease\(^{34,57}\) as risk factors for severity or death with COVID-19. Recently developed scoring systems for outpatients identified increase age, comorbidities and symptoms like dyspnea and fever to be predictable for increased risk for hospitalization in outpatients\(^{38–39}\). This is in line with our data too.

Our study has several limitations. One limitation is a consequence from the very dynamic development of the pandemic. We recruited participants during the second wave of the infection, which in Germany was caused by the initial strain of the virus and therewith may be not directly transferable to the current infections with the delta or omicron strain. This limitation impacts not just our study but the majority of the currently published studies that collected data during the first wave of the pandemic\(^{37,40–42,60}\).
Because of the outpatient setting, we were unable to collect biological samples which would be of interest for some risk scores. Another clear limitation is the questionnaire design of the study, which relies on self-reporting and thus may not perfectly reflect actual frequencies of different symptoms. We also did not ask about the intensity of the symptoms. However, without the possibility to apply precise and accurate standardized measurements, self-described severity of the symptoms is subjective and may be of limited use.

In conclusion, our study of SARS-CoV-2 patients with mild and moderate course of infection confirms the delayed onset of loss of smell and loss of taste and strengthens dyspnea and vomiting as symptoms associated with an increased risk of hospitalization. Our data also suggest that disability in general may be a useful marker for increased risk of hospitalization. Finally and most importantly, although preliminary, our data points to different roles of loss of smell and loss of taste as predictors for the severity of the infection.

**Data availability**

The data contains sensitive information about the health of the study participants that cannot be deposited openly. However, individual-level data that support the findings of this study could be obtained from corresponding author following an approval of the steering committee of the University Medicine Greifswald.

Received: 7 November 2021; Accepted: 11 April 2022
Published online: 04 May 2022

**References**

1. Medicine, J.H.U. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) (2021). https://coronavirus.jhu.edu/map.html. Accessed 20 Apr 2022.
2. Koh, J. et al. Epidemiological and clinical characteristics of cases during the early phase of COVID-19 pandemic: A systematic review and meta-analysis. *Front. Med. (Lausanne)* 7, 295 (2020).
3. Smith, D. S., Richey, E. A. & Brunetto, W. A symptom-based rule for diagnosis of COVID-19. *SN Compr. Clin. Med.* 2(11), 1–8 (2020).
4. de Lusignan, S. et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: A cross-sectional study. *Lancet Infect. Dis.* 20(9), 1034–1042 (2020).
5. Docherty, A. B. et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. *BMJ* 369, m1985 (2020).
6. Killerby, M. E. et al. Characteristics associated with hospitalization among patients with COVID-19—Metropolitan Atlanta, Georgia, March-April 2020. *Morb. Mortal Wkly. Rep.* 69(25), 790–794 (2020).
7. Robert-Koch-Institut. Coronavirus Disease 2019 (COVID-19) Daily Situation Report by the Robert Koch Institute 27/09/2021—Current Status for Germany (Robert-Koch-Institut, 2021).
8. Donnelly, J. P. et al. Readmission and death after initial hospital discharge among patients with COVID-19 in a large multihospital system. *JAMA* 325(3), 304–306 (2021).

| Risk factor | Individuals with this risk factor* | Univariate analyses | Multivariate analyses*** |
|------------|-----------------------------------|--------------------|-------------------------|
|            | OR (95% CI)                         | p-value            | OR (95% CI)             | p-value |
| Age ≥ 60   | 329 (39.5%)                         | 5.66 (3.93–8.15)   | < 10⁻⁶                   | 3.52 (2.02–6.20) | 1.3 x 10⁻⁵ |
| Male sex   | 365 (43.6%)                         | 2.31 (1.65–3.24)   | 8.0 x 10⁻⁴              |         |
| Cardiovascular diseases | 132 (15.9%)     | 4.70 (3.16–6.99)   | 6.5 x 10⁻⁶              | 1.84 (1.05–3.23) | 0.03 |
| Hypertension | 345 (41.4%) | 2.47 (1.75–3.46)   | 1.3 x 10⁻⁵              |         |
| Peripheral artery disease | 17 (2.0%)     | 4.47 (1.70–11.8)   | 0.001                   |         |
| Diabetes mellitus | 94 (11.3%) | 4.54 (2.90–7.10)   | 1.6 x 10⁻⁴              | 2.41 (1.32–4.39) | 0.004 |
| Pulmonary disease | 97 (11.6%) | 2.68 (1.71–4.20)   | 1.0 x 10⁻⁵              |         |
| COPD       | 20 (2.4%)                           | 23.1 (6.69–79.7)   | 1.8 x 10⁻⁶              | 5.95 (1.36–26.2) | 0.02 |
| Asthma     | 38 (4.5%)                           | 0.55 (0.21–1.43)   | ns                      |         |
| Neurological disease | 88 (10.6%) | 5.81 (3.66–9.21)   | 4.5 x 10⁻⁶              | 3.22 (1.70–6.09) | 3.4 x 10⁻⁴ |
| Stroke     | 27 (3.3%)                           | 6.16 (2.80–13.54)  | 3.5 x 10⁻⁵              |         |
| Neurological disease and stroke | 69 (8.3%)      | 5.49 (3.30–9.14)   | 8.7 x 10⁻⁵              |         |
| Neurological disease other than stroke | 61 (7.2%)     | 4.71 (2.76–8.04)   | 9.2 x 10⁻⁶              |         |
| Kidney diseases | 59 (7.1%)      | 5.00 (2.90–8.59)   | 3.1 x 10⁻⁶              | 2.48 (1.19–5.15) | 0.02 |
| Disability** | 137 (19.7%)     | 3.56 (1.79–7.07)   | 1.3 x 10⁻⁴              |         |
| ACE or AT1 inhibitors | 264 (50.5%) | 2.23 (1.46–3.41)   | 1.8 x 10⁻⁴              |         |
| ACE inhibitors | 133 (25.4%) | 1.78 (1.14–2.78)   | 0.01                    |         |
| AT1 antagonists | 133 (25.4%) | 1.53 (0.97–2.39)   | ns                      |         |

Table 3: Comorbidities as risk factors for hospitalization. ns not significant. *Percentages were calculated based on those individuals that answered the question. **Disability of any kind was documented only in the COVER study, not the VIP study. ***Multivariate analyses were performed using binary logistic regression with forward inclusion.
9. Schuling, J. et al., Krankheitsschwere der ersten COVID-19-Welle in Deutschland basierend auf den Meldungen gemäß Infektions-schutzgesetz (2020).
10. Zha, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382(8), 727–733 (2020).
11. Garibaldi, B. T. et al. Patient trajectories among persons hospitalized for COVID-19: A cohort study. Ann. Intern. Med. 174(1), 33–41 (2021).
12. Knight, S. R. et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C mortality score. BMJ 370, 3339 (2020).
13. Gupta, R. K. et al. Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: A prospective cohort study. Lancet Respir. Med. 9(4), 349–359 (2021).
14. Knight, S. R. et al. Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO clinical characterisation protocol. Thorax. https://doi.org/10.1136/thoraxjnl-2021-217629 (2021).
15. Haruyanto, T. I., Rizki, N. A. & Kurniawan, A. Anosmia/hyposmia is a good predictor of coronavirus disease 2019 (COVID-19) Infection: A meta-analysis. Int. Arch. Otorhinolaryngol. 25(1), e170–e174 (2021).
16. Dantas, L. F. et al. App-based symptom tracking to optimize SARS-CoV-2 testing strategy using machine learning. PLoS ONE 16(3), e0248920 (2021).
17. Schneider, A. et al. Covid-19 in outpatients-Is fever a useful indicator for SARS-CoV-2 infection? PLoS ONE 16(2), e0246312 (2021).
18. Santos, R. E. A. et al. Onset and duration of symptoms of loss of smell/taste in patients with COVID-19: A systematic review. Am. J. Otolaryngol. 42(2), 102889 (2021).
19. Amanat, M. et al. Neurological manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: A multicenter prospective clinical study. BMC Neurol. 21(1), 116 (2021).
20. Yan, C. H. et al. Self-reported olfactory loss associates with outpatient clinical course in COVID-19. Int. Forum Allergy Rhinol. 10(7), 821–831 (2020).
21. Giorli, A. et al. A literature systematic review with meta-analysis of symptoms prevalence in covid-19: The relevance of olfactory symptoms in infection not requiring hospitalization. Curr. Treat Opt. Neurol. 22(10), 36 (2020).
22. Vaïra, L. A. et al. Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study. Head Neck 42(7), 1560–1569 (2020).
23. Hopkins, C., Vaïra, L. A. & De Riu, G. Self-reported olfactory loss in COVID-19: Is it really a favorable prognostic factor? Int. Forum Allergy Rhinol. 10(7), 926 (2020).
24. Heckmann, J. G. et al. Neurological aspects of taste disorders. Arch. Neurol. 69(5), 667–671 (2003).
25. Cutsforth-Gregory, J. K. & Benaroch, E. E. Nucleus of the solitary tract, medullary reflexes, and clinical implications. Neurology 88(12), 1187–1196 (2017).
26. King, T. L. et al. Hypoxia activates nucleus tractus solitarii neurons projecting to the paraventricular nucleus of the hypothalamus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302(10), R1219–R1232 (2012).
27. Bocci, T. et al. Brainstem clinical and neurophysiological involvement in COVID-19. J. Neurol. 268(10), 3598–3600 (2021).
28. Luccheser, G. & Floel, A. Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons. Autoimmun. Rev. 19(7), 102556 (2020).
29. Aigbti, I. S. et al. Prevalence, severity and mortality associated with copd and smoking in patients with COVID-19: A rapid systematic review and meta-analysis. PLoS ONE 15(5), e0233147 (2020).
30. Gerayeli, F. V. et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine 33, 100789 (2021).
31. Harrison, S. L. et al. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med. 17(9), e1003321 (2020).
32. Khan, M. M. A. et al. Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: A systematic review and meta-analysis. J. Glob. Health 10(2), 020503 (2020).
33. Lee, S. C. et al. Impact of COPD on COVID-19 prognosis: A nationwide population-based study in South Korea. Sci. Rep. 11(1), 37335 (2021).
34. Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584(7821), 430–436 (2020).
35. Kaeuffer, C. et al. Clinical characteristics and risk factors associated with severe COVID-19: Prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020. Euro Surveill. 25(48), 2000895 (2020).
36. Li, X. et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J. Allergy Clin. Immunol. 146(1), 110–118 (2020).
37. Zeng, W. et al. Gastrointestinal symptoms are associated with severity of coronavirus disease 2019: A systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 34, 168 (2021).
38. Aziz, M. et al. Gastrointestinal predictors of severe COVID-19: Systematic review and meta-analysis. Ann. Gastroenterol. 33(6), 615–630 (2020).
39. Semenzato, L. et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: A cohort study of 66 million people. Lancet Reg. Health Eur. 8, 100158 (2021).
40. Vahey, G. M. et al. Symptom profiles and progression in hospitalized and nonhospitalized patients with coronavirus disease, Colorado, USA, 2020. Emerg. Infect. Dis. 27(2), 385–395 (2021).
41. Prado-Galbarro, F. J. et al. Determinants of survival after severe acute respiratory syndrome coronavirus 2 infection in Mexican outpatients and hospitalised patients. Public Health 189, 66–72 (2020).
42. Potrilli, C. M. et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. BMJ 369, m1966 (2020).
43. Halalau, A. et al. Epidemiology, clinical characteristics, and outcomes of a large cohort of COVID-19 outpatients in Michigan. Int. J. Gen. Med. 14, 1555–1563 (2021).
44. Badve, M. S. et al. Frequency of post-stroke pneumonia: Systematic review and meta-analysis of observational studies. Int. J. Stroke 14(2), 125–136 (2019).
45. Westendorp, W. F. et al. Post-stroke infection: A systematic review and meta-analysis. BMC Neurol. 11, 110 (2020).
46. Yuan, M. Z. et al. Risk factors for lung infection in stroke patients: A meta-analysis of observational studies. Expert Rev. Anti Infect. Ther. 13(10), 1289–1298 (2015).
47. Ennsley, H. C. & Hopkins, S. J. Acute ischaemic stroke and infection: Recent and emerging concepts. Lancet Neurol. 7(4), 341–355 (2008).
48. Ma, A. et al. Stroke and thromboprophylaxis in the era of COVID-19. J. Stroke Cerebrovasc. Dis. 30(1), 105392 (2021).
49. Wichmann, D. et al. Autopsy findings and venous thromboembolism in patients with covid-19: A prospective cohort study. Ann. Intern. Med. 173(4), 268–277 (2020).
50. Gleason, J. et al. The devastating impact of Covid-19 on individuals with intellectual disabilities in the United States. NEJM Catal. Innov. Care Deliv. https://doi.org/10.1056/CAT.21.0051 (2021).
51. Cittadini, L. et al. COVID-19 mortality risk in down syndrome: Results from a cohort study of 8 million adults. Ann. Intern. Med. 174(4), 572–576 (2021).
52. Huang, S. et al. COVID-19 patients with hypertension have more severe disease: A multicenter retrospective observational study. *Hypertens. Res.* **43**(8), 824–831 (2020).
53. Guo, L. et al. Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: A meta-analysis. *Diabetes Res Clin Pract* **166**, 108346 (2020).
54. Roncon, L. et al. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. *J. Clin. Virol.* **127**, 104354 (2020).
55. Guan, W. J. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. *Eur. Respir. J.* **55**(5), 2000547 (2020).
56. Leung, J. M. et al. COVID-19 and COPD. *Eur. Respir. J.* **56**(2), 2002108 (2020).
57. Cheng, Y. et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int.* **97**(5), 829–838 (2020).
58. Ebll, M. H., Hamadani, R. & Kieber-Emmons, A. Simple risk scores to predict hospitalization or death in outpatients with COVID-19. *MedRxiv*. https://doi.org/10.1101/2022.01.14.22269295 (2022).
59. Jacquerioz, F. et al. Development and validation of the OUTCoV score to predict the risk of hospitalisation among patients with SARS-CoV-2 infection in ambulatory settings: A prospective cohort study. *BMJ Open* **11**(6), e044242 (2021).
60. Wiegele, P. N. et al. Symptom diary-based analysis of disease course among patients with mild coronavirus disease, Germany, 2020. *Emerg. Infect. Dis.* **27**(5), 1353–1361 (2021).

Acknowledgements
We are very grateful for the excellent technical support of our study nurse Andrea Seidel. We are grateful to the medical staff and especially to Dr. Marlies Kühn from the health department (Gesundheitsamt) in the district of Vorpommern-Greifswald for the support in contacting the participants. Without their support, this study will not be possible. We also express our gratitude to all the study participants for taking time to participate, documenting their symptoms daily despite illness and psychological stress, to help us to understand better the disease. We acknowledge support for the Article Processing Charge from the DFG (German Research Foundation, 393148499) and the Open Access Publication Fund of the University of Greifswald.

Author contributions
E.S.: designed the study, collect the data, analysed the data, and wrote the manuscript. M.T.: designed the study, analysed the data, and wrote the manuscript. C.S., M.Napp, L.F.-L., D.S.: collect the data. K.H., W.H., U.V., M.Nauck, K.S., B.R., S.F.: designed the study. A.Fritz: analysed the data. A.Flöel, G.L., N.H., S.E. and T.K.: analysed the data and wrote the manuscript. All authors: revised and approved the manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-11103-0.

Correspondence and requests for materials should be addressed to M.V.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022